Cunha Vanessa Vasconcelos, Silva Paulo Goberlânio de Barros, Lemos José Vitor Mota, Martins Joyce Ohana Lima, Freitas Milena Oliveira, Avelar Rafael Linard
Fellow Master degree, Academic Master in Dental Sciences, School of Dentistry, Centro Universitário Christus (UNICHRISTUS), Fortaleza-CE, Brazil. Substantive scientific and intellectual contributions to the study.
Professor, Division of Oral and Maxillofacial Surgery, School of Dentistry, UNICHRISTUS, Fortaleza-CE, Brazil. Critical revision, final approval.
Acta Cir Bras. 2020 Nov 30;35(10):e202001005. doi: 10.1590/s0102-865020200100000005. eCollection 2020.
To assess the effect of a collagen matrix (Mucograft®) on the inflammatory process in a semi-critical experimental defect model in rats treated with bisphosphonates.
Eighteen Wistar rats were randomly divided into three groups: saline (CG), alendronate (ALD) 5mg/kg (AG) or zoledronic acid (ZA) 0.2mg/kg (ZG). ALD was administered orally for 10 weeks and ZA was administered intravascularly on days 0, 7 and 14 and 49. On day 42, a 2mm defect was created and filled with Mucograft® collagen matrix. The contralateral side was filled with a clot (control side). The animals were euthanized 70 days after the beginning of the experiment and the hemimandibles were radiographically and histologically (counting of empty osteocyte lacunae (%), apoptotic (%) and total osteoclasts, neutrophil and mononuclear inflammatory cells) analyzed. The variables were submitted to ANOVA/Bonferroni and t test (parametric data) (p <0.05, GraphPad Prism 5.0).
Significant bone repair occurred in the groups treated with Mucograft®. High number of total inflammatory cells and neutrophils cells were showed in AG (p=0.026 and p=0.035) and AZ groups (p=0.005, p=0.034) on the control sides associated with delayed bone repair and the presence of devitalized bone tissue in AG and ZG on the Mucograft® side.
Mucograft® collagen matrix attenuated the inflammatory process in a mandible defect in rats submitted to the use of bisphosphonates (AG and ZG).
评估胶原蛋白基质(Mucograft®)对双膦酸盐治疗的大鼠半临界实验性缺损模型中炎症过程的影响。
将18只Wistar大鼠随机分为三组:生理盐水组(CG)、阿仑膦酸钠5mg/kg组(AG)或唑来膦酸0.2mg/kg组(ZG)。AG口服给药10周,ZG在第0、7、14和49天进行血管内给药。在第42天,制造一个2mm的缺损并用Mucograft®胶原蛋白基质填充。对侧用血凝块填充(对照侧)。实验开始70天后对动物实施安乐死,并对下颌骨进行影像学和组织学分析(计数空骨陷窝百分比(%)、凋亡百分比(%)以及破骨细胞、中性粒细胞和单核炎症细胞总数)。对变量进行方差分析/邦费罗尼检验和t检验(参数数据)(p<0.05,GraphPad Prism 5.0)。
使用Mucograft®治疗的组出现了显著的骨修复。在对照侧,AG组(p=0.026和p=0.035)和AZ组(p=0.005,p=0.034)显示出大量的总炎症细胞和中性粒细胞,这与骨修复延迟以及AG组和ZG组在Mucograft®侧存在失活骨组织有关。
Mucograft®胶原蛋白基质减轻了使用双膦酸盐(AG和ZG)的大鼠下颌骨缺损中的炎症过程。